Risk factors and the prognosis of sexual dysfunction in male patients with pituitary adenomas: a multivariate analysis

Zhou, Wenqiang; Ma, Shunchang; Zhao, Min; Liu, Chang; Guan, Xiudong; Bao, Zhaoshi; Jia, Guijun; Jia, Wang

doi:10.4103/aja.aja_18_17

Cited by 14 publications

(2 citation statements)

References 31 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prolactinoma is the most frequent pituitary neuroendocrine tumor, and recent epidemiological reviews have estimated that this tumor subtype accounts for 53% of pituitary neuroendocrine tumors (Inder & Jang, 2022). Prolactinoma causes various serious hazards to mankind’s health, for instance, amenorrhea, sexual dysfunction, galactorrhea, hyperprolactinemia, and infertility (Maiter, 2016; Zhou et al, 2018). In China, bromocriptine is a first-line drug against prolactinoma.…”

Section: Introductionmentioning

confidence: 99%

Network Pharmacology to Explore the Mechanism of Prunella vulgaris L. Against Prolactinoma

Meng,

Ni,

Cao

et al. 2023

Pharmacognosy Magazine

View full text Add to dashboard Cite

Objectives Prolactinoma is a common intracranial tumor with a high incidence and serious harm to human health. At present, there is only one therapeutic drug in China, bromocriptine, and the Chinese herb Prunella vulgaris L.( P. vulgaris)(PV) has shown certain anti-prolactinoma effects in the early stage. We expect to develop a candidate drug against prolactinoma. Materials and Methods First, the extracts of P. vulgaris L.(PVE)were extracted with water, and the cell proliferation test of rat pituitary tumor cells MMQ was checked by the Cell Counting Kit-8 (CCK-8) assay. Then, core targets and correlative pathways were selected by the “protein–protein interaction” (PPI) network and the “PV–Target–Prolactinoma” network. The core targets and main components simulate the binding by molecular docking. Finally, the PVE and MMQ cells were used to verify the results. Results Through the CCK-8 assay, the PVE inhibited the proliferation of MMQ cells. From the network pharmacology, the 21 targets, 9 signaling pathways, and 20 gene ontology (GO) projects were attained ( p < .05). As a result the estrogen receptor α (ESR1), RAC-alpha serine/threonine-protein kinase(AKT1), and mitogen-activated protein kinase 3(MAPK3)were the core targets of protein against prolactinomas, which was in line with western blotting analysis. Conclusion Our findings demonstrate that the PVE was verified against prolactinomas through the ESR1, MAPK3 targets, and the phosphoinositide 3-kinase/protein kinase B pathway.

show abstract

Section: Introductionmentioning

confidence: 99%

Network Pharmacology to Explore the Mechanism of Prunella vulgaris L. Against Prolactinoma

Meng,

Ni,

Cao

et al. 2023

Pharmacognosy Magazine

View full text Add to dashboard Cite

show abstract

“…Bromocriptine is the only available drug for the treatment of prolactinoma in China, and drug resistance often occurs [5,6]. Prolactinomas cause severe harm to the human body with various symptoms, such as amenorrhea, galactorrhea, sexual dysfunction, infertility and hyperprolactinemia [7][8][9]. At present, the pathogenesis of prolactinoma is not clear, and the drug development and clinical therapeutic target exploration need to be studied urgently.…”

Section: Introductionmentioning

confidence: 99%

Estrogen Promotes Pituitary Prolactinoma by Upregulating TLR4 / NF-κB/p38MAPK Pathway

Ding

Wang

Wu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Prolactinomas have harmful effects on human health, and the pathogenesis is still unknown. Furthermore, the morbidity of women is much more than man, maybe related with estradiol level. Thus, it is important to reveal the pathogenesis and develop new therapeutic methods for prolactinomas.Methods: Immunofluorescence analysis or Immunohistochemistry analysis were performed on the ERβ, TLR4 and prolactin (PRL) expressions of pituitary gland in C57BL/6 mice and human prolactinoma specimen. In the present study, the role of TLR4 in prolactinoma was determined using estradiol-induced mice models in C57BL/6 wild-type (WT) and TLR4−/− mice. MMQ cells were treated with estradiol, fulvestrant, LPS or transfected with different TLR4 small interfering RNA, which to study ERβ, TLR4 and PRL expression in MMQ cells. Co‑immunoprecipitates analysis was used to investigate the interaction between ERβ and TLR4.Results: Immunofluorescence analysis or Immunohistochemistry analysis showed that PRL and TLR4 expression were co-located and increased in the pituitary gland of mice and human prolactinoma specimen compared with the control specimen. It was shown that PRL and TLR4 expression was co-located and increased significantly in the pituitary gland of estradiol-injected prolactinoma mice compared with the control mice. Knockout of TLR4 significantly inhibited tumor overgrowth, and PRL expression was decreased in estradiol-induced mice through regulating TLR4/NF‑κB/p38MAPK pathway. Estradiol promoted PRL expression through regulating TLR4/NF‑κB/p38MAPK pathway in vitro study, and pre-Inhibiting ERβ or TLR4 reverse the effect, while simultaneously activating ERβ and TLR4 enhanced PRL expression than activating single ERβ or TLR4. Furthermore, ERβ co-immunoprecipitates with endogenous TLR4 was assessed by co-immunoprecipitation analysis.Conclusions: These results suggest that estradiol promoted prolactinoma development by activating the TLR4/NF‑κB/ p38MAPK pathway through Erβ and TLR4 knockout inhibited the proliferation and secretion of prolactin in prolactinoma.

show abstract

Endocrine Disorders and Sexuality I: Hypothalamus-Pituitary Axes and Peripheral Thyroid and Adrenal Glands

Mora Porta,

Hanzu,

Orois Añón

2024

Trends in Andrology and Sexual Medicine

View full text Add to dashboard Cite

Risk factors and the prognosis of sexual dysfunction in male patients with pituitary adenomas: a multivariate analysis

Cited by 14 publications

References 31 publications

Network Pharmacology to Explore the Mechanism of Prunella vulgaris L. Against Prolactinoma

Network Pharmacology to Explore the Mechanism of Prunella vulgaris L. Against Prolactinoma

Estrogen Promotes Pituitary Prolactinoma by Upregulating TLR4 / NF-κB/p38MAPK Pathway

Endocrine Disorders and Sexuality I: Hypothalamus-Pituitary Axes and Peripheral Thyroid and Adrenal Glands

Contact Info

Product

Resources

About